Treatment of occluded central venous catheters with alteplase: Results in 1,064 patients

Journal of Vascular and Interventional Radiology

Volumn 13, Issue 12, 2002, Pages 1199-1205

  Semba, Charles P ^a,b   Deitcher, Steven R ^c   Li, Xin ^a   Resnansky, Laura ^a   Tu, Tri ^a   McCluskey, Edward R ^a  

^a GENENTECH INC   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Thrombolysis; Tissue type plasminogen activator

Indexed keywords

ALTEPLASE;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; BRAIN HEMORRHAGE; CENTRAL VENOUS CATHETER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOSIS;

EID: 0036899572     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61965-4     Document Type: Article

References (11)

1. Reeves AR, Seshadri R, Trerotola SO. Recent trends in central venous catheter placement: A comparison of interventional radiology with other specialties. J Vasc Interv Radiol 2001; 12:1211-1214.
2. Silberzweig JE, Sacks D, Khorsandi AS, Bakal CW. Reporting standards for central venous access. J Vasc Interv Radiol 2000; 11:391-400.
3. US Food and Drug Administration Med Watch. Important Drug Warning: Safety Information Regarding Use of Abbokinase (Urokinase). Available at: www.fda.gov/cber/ltr/abb012599.htm. Accessed September 2002.
4. US Food and Drug Administration Med Watch. Important Safety Information - Letter: Dear Hospital Pharmacy and Physician (AstraZeneca, Inc.), December 10, 1999. Available at: www.fda.gov/medwatch/safety/1999/ strept.htm. Accessed September 2002.
5. Haire WD, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: A double-blinded, randomized trial. Thromb Haemost 1994; 72:543-547.
6. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: A double-blind placebo-controlled trial. J Vasc Interv Radiol 2001; 12:951-955.
7. Deitcher SR, Fesen MR, Kiproff PM, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters. J Clin Oncol 2002; 20:317-324.
8. Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojick J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol 1992; 19:1071-1075.
9. Jacobs BR, Haygood M, Hingl J. Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in children. J Pediatr 2001; 139:593-596.
10. Clase CM, Crowther MA, Ingram AJ, Cina CS. Thrombolysis for restoration of patency to hemodialysis central venous catheters: A systematic review. J Thromb Thrombolysis 2001; 11:127-136.
11. Schenk P, Rosenkranz AR, Wolfl G, Horl WH, Traindl O. Recombinant tissue plasminogen activator is a useful alternative to heparin in priming Quinton Permcath. Am J Kidney Dis 2000; 35:130-136.